biotech · Genetic Disease · Alport Syndrome · ELOX
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Watertown, USA
- Founded
- 2013
- Employees
- 12
- Programs
- 7
- Drugs
- 1
- Patents
- 6
Eloxx Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Eloxx Pharmaceuticals.
Eloxx Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ELX-02
Eloxx Pharmaceuticals
Cystic Fibrosis
2 trials -
ELX-02
Eloxx Pharmaceuticals
Genetic Disease
2 trials -
ELX-02
Eloxx Pharmaceuticals
Alport Syndrome
1 trial -
Exaluren
Eloxx Pharmaceuticals
Alport Syndrome, X-Linked
1 trial -
ELX-02
Eloxx Pharmaceuticals
Genetic Diseases
1 trial -
ELX-02
Eloxx Pharmaceuticals
Impaired Renal Function
1 trial -
Placebo
Eloxx Pharmaceuticals
Genetic Disease
1 trial
Frequently asked questions
How many clinical projects does Eloxx Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.